Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Apellis Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Apellis Pharmaceuticals, Inc.’s stock price such as:

• Apellis Pharmaceuticals, Inc.’s current stock price and volume
• Why Apellis Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for APLS from analysts
• APLS’s stock price momentum as measured by its relative strength

About Apellis Pharmaceuticals, Inc. (APLS)

Before we jump into Apellis Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Want to learn more about Apellis Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 3:31 PM, CST, Apellis Pharmaceuticals, Inc.’s stock price was $21.600.

Apellis Pharmaceuticals, Inc. is up 2.86% from its previous closing price of $21.000.

During the last market session, Apellis Pharmaceuticals, Inc.’s stock traded between $20.900 and $21.710. Currently, there are approximately 126.42 million shares outstanding for Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 58.7, which is high compared to the Biotechnology industry median of 19.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Apellis Pharmaceuticals, Inc. Stock Price History

Apellis Pharmaceuticals, Inc.’s (APLS) price is currently up 0.61% so far this month.

During the month of November, Apellis Pharmaceuticals, Inc.’s stock price has reached a high of $21.710 and a low of $18.755.

Over the last year, Apellis Pharmaceuticals, Inc. has hit prices as high as $35.720 and as low as $16.100. Year to date, Apellis Pharmaceuticals, Inc.’s stock is down 32.31%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Apellis Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 25, 2025, there were 2 analysts who downgraded Apellis Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Apellis Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Apellis Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Apellis Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Apellis Pharmaceuticals, Inc. (APLS) by visiting AAII Stock Evaluator.

Relative Price Strength of Apellis Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 25, 2025, Apellis Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -11.40%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how Apellis Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Apellis Pharmaceuticals, Inc. Stock Price: Bottom Line

As of November 26, 2025, Apellis Pharmaceuticals, Inc.’s stock price is $21.600, which is up 2.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Apellis Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.